CRISPR Therapeutics AG (CRSP) Increases Despite Market Slip: Here's What You Need to Know

The most recent trading session ended with CRISPR Therapeutics AG (CRSP) standing at $39.36, reflecting a +1.84% shift from the previouse trading day's closing. The stock exceeded the S&P 500, which registered a loss of 0.43% for the day. Meanwhile, the Dow lost 0.07%, and the Nasdaq, a tech-heavy index, lost 0.9%.Shares of the company have depreciated by 29.92% over the course of the past month, underperforming the Medical sector's loss of 7.03% and the S&P 500's loss of 1.98%.The upcoming earnings release of CRISPR Therapeutics AG will be of great interest to investors. The company is forecasted to report an EPS of -$1.20, showcasing a 209.09% downward movement from the corresponding quarter of the prior year. Meanwhile, the latest consensus estimate predicts the revenue to be $12.18 million, indicating a 93.95% decrease compared to the same quarter of the previous year.Regarding the entire year, the Zacks Consensus Estimates forecast earnings of -$5.13 per share and revenue of $16.58 million, indicating changes of -164.43% and -95.53%, respectively, compared to the previous year.Investors might also notice recent changes to analyst estimates for CRISPR Therapeutics AG. These revisions typically reflect the latest short-term business trends, which can change frequently. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system.The Zacks Rank system, ranging from #1 (Strong Buy) to #5 (Strong Sell), possesses a remarkable history of outdoing, externally audited, with #1 stocks returning an average annual gain of +25% since 1988. Over the past month, there's been a 0.1% rise in the Zacks Consensus EPS estimate. Currently, CRISPR Therapeutics AG is carrying a Zacks Rank of #3 (Hold).The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 59, finds itself in the top 24% echelons of all 250+ industries.The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.Don't forget to use Zacks.com to keep track of all these stock-moving metrics, and others, in the upcoming trading sessions.Only $1 to See All Zacks' Buys and SellsWe're not kidding.Several years ago, we shocked our members by offering them 30-day access to all our picks for the total sum of only $1. No obligation to spend another cent.Thousands have taken advantage of this opportunity. Thousands did not - they thought there must be a catch. Yes, we do have a reason. We want you to get acquainted with our portfolio services like Surprise Trader, Stocks Under $10, Technology Innovators,and more, that closed 228 positions with double- and triple-digit gains in 2023 alone.See Stocks Now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report CRISPR Therapeutics AG (CRSP): Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks